Posted by Michael Wonder on 15 Jul 2025
ICER publishes final evidence report on treatment for secondary progressive multiple sclerosis
15 July 2025 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit of tolebrutinib compared to best supportive care.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of for the treatment of tolebrutinib (Sanofi) for the treatment of secondary progressive multiple sclerosis.
